EC Approves Frontline Pembrolizumab for PD-L1+ Metastatic NSCLC

January 31st, 2017 – The European Commission has expanded the indication for pembrolizumab to include the frontline treatment of patients with metastatic non–small cell lung cancer (NSCLC) that expresses PD-L1 on ≥50% of cells and does not harbor an EGFR or ALK mutation. The approval was based on data from phase III KEYNOTE-024 trial, and followed a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), which … (leggi tutto)